ALEXANDRIA, Va., Feb. 12 -- United States Patent no. 12,220,409, issued on Feb. 11, was assigned to ARCUTIS BIOTHERAPEUTICS INC. (Westlake Village, Calif.).
"Roflumilast formulations with an improved pharmacokinetic profile" was invented by David Osborne (Fort Collins, Colo.).
According to the abstract* released by the U.S. Patent & Trademark Office: "An improved method is provided for treating a patient having a disorder responsive to PDE-4 inhibition by administering roflumilast. The improvement involves administering the roflumilast topically in a composition having a roflumilast release profile that produces in the patient a flattened plasma concentration time curve and a reduced Cmax relative to oral administration of a PDE4-inhibiti...